Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -51.05 Million USD | -2.58% |
| 2022 | -49.77 Million USD | 75.49% |
| 2021 | -203.06 Million USD | -957.67% |
| 2020 | -19.19 Million USD | 17.71% |
| 2019 | -23.33 Million USD | 12.34% |
| 2018 | -26.61 Million USD | 24.94% |
| 2017 | -35.45 Million USD | 6.75% |
| 2016 | -38.02 Million USD | -3.67% |
| 2015 | -36.67 Million USD | 17.99% |
| 2014 | -44.72 Million USD | -19.21% |
| 2013 | -37.51 Million USD | 18.1% |
| 2012 | -45.8 Million USD | -124.09% |
| 2011 | -20.44 Million USD | 16.86% |
| 2010 | -24.58 Million USD | 61.12% |
| 2009 | -63.23 Million USD | -69.28% |
| 2008 | -37.35 Million USD | 7.34% |
| 2007 | -40.31 Million USD | -29.1% |
| 2006 | -31.23 Million USD | -13.61% |
| 2005 | -27.48 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.14 Million USD | 33.59% |
| 2024 Q2 | -9.83 Million USD | -7.54% |
| 2023 Q3 | -12.6 Million USD | -0.93% |
| 2023 Q1 | -12.9 Million USD | -22.79% |
| 2023 Q2 | -12.48 Million USD | 3.29% |
| 2023 FY | -51.05 Million USD | -2.58% |
| 2023 Q4 | -13.76 Million USD | -9.25% |
| 2022 Q2 | -10.58 Million USD | 0.73% |
| 2022 FY | -49.77 Million USD | 75.49% |
| 2022 Q1 | -10.66 Million USD | 6.88% |
| 2022 Q4 | -10.51 Million USD | 39.61% |
| 2022 Q3 | -17.4 Million USD | -64.51% |
| 2021 Q2 | -9.17 Million USD | 88.43% |
| 2021 Q1 | -79.23 Million USD | -1160.64% |
| 2021 Q4 | -11.44 Million USD | 23.25% |
| 2021 Q3 | -14.91 Million USD | -62.64% |
| 2021 FY | -203.06 Million USD | -957.67% |
| 2020 Q4 | -6.28 Million USD | -54.08% |
| 2020 Q1 | -4.41 Million USD | 17.56% |
| 2020 FY | -19.19 Million USD | 17.71% |
| 2020 Q2 | -4.23 Million USD | 4.1% |
| 2020 Q3 | -4.07 Million USD | 3.71% |
| 2019 Q2 | -6.35 Million USD | -3.77% |
| 2019 Q3 | -6.01 Million USD | 5.34% |
| 2019 Q4 | -5.35 Million USD | 10.89% |
| 2019 FY | -23.33 Million USD | 12.34% |
| 2019 Q1 | -6.12 Million USD | 2.72% |
| 2018 Q3 | -6.79 Million USD | 4.64% |
| 2018 FY | -26.61 Million USD | 24.94% |
| 2018 Q2 | -7.12 Million USD | 5.65% |
| 2018 Q1 | -7.55 Million USD | -9.43% |
| 2018 Q4 | -6.29 Million USD | 7.42% |
| 2017 Q4 | -6.9 Million USD | 33.92% |
| 2017 Q3 | -10.44 Million USD | -13.73% |
| 2017 FY | -35.45 Million USD | 6.75% |
| 2017 Q2 | -9.18 Million USD | 10.97% |
| 2017 Q1 | -10.31 Million USD | -14.5% |
| 2016 Q4 | -9.01 Million USD | 4.41% |
| 2016 Q3 | -9.42 Million USD | 13.69% |
| 2016 FY | -38.02 Million USD | -3.67% |
| 2016 Q2 | -10.92 Million USD | -5.18% |
| 2016 Q1 | -10.38 Million USD | 12.09% |
| 2015 FY | -36.67 Million USD | 17.99% |
| 2015 Q3 | -7.25 Million USD | 21.0% |
| 2015 Q4 | -11.81 Million USD | -62.83% |
| 2015 Q2 | -9.18 Million USD | 1.98% |
| 2015 Q1 | -9.36 Million USD | -473.26% |
| 2014 Q2 | -12.25 Million USD | 18.97% |
| 2014 FY | -44.72 Million USD | -19.21% |
| 2014 Q1 | -15.12 Million USD | -93.85% |
| 2014 Q4 | -1.63 Million USD | 89.6% |
| 2014 Q3 | -15.71 Million USD | -28.28% |
| 2013 Q4 | -7.8 Million USD | 6.05% |
| 2013 Q3 | -8.3 Million USD | 7.32% |
| 2013 FY | -37.51 Million USD | 18.1% |
| 2013 Q2 | -8.95 Million USD | 28.08% |
| 2013 Q1 | -12.45 Million USD | -1641.46% |
| 2012 Q3 | -25.46 Million USD | -214.82% |
| 2012 FY | -45.8 Million USD | -124.09% |
| 2012 Q4 | 808 Thousand USD | 103.17% |
| 2012 Q1 | -18.69 Million USD | -113.94% |
| 2012 Q2 | -8.08 Million USD | 56.74% |
| 2011 Q3 | -5.01 Million USD | 39.05% |
| 2011 Q1 | 1.84 Million USD | 118.27% |
| 2011 Q2 | -8.22 Million USD | -547.12% |
| 2011 FY | -20.44 Million USD | 16.86% |
| 2011 Q4 | -8.74 Million USD | -74.31% |
| 2010 Q2 | -4.78 Million USD | -2.93% |
| 2010 FY | -24.58 Million USD | 61.12% |
| 2010 Q4 | -10.07 Million USD | -98.11% |
| 2010 Q3 | -5.08 Million USD | -6.27% |
| 2010 Q1 | -4.64 Million USD | -15.03% |
| 2009 FY | -63.23 Million USD | -69.28% |
| 2009 Q3 | -4.94 Million USD | 78.37% |
| 2009 Q2 | -22.87 Million USD | -121.18% |
| 2009 Q1 | -10.34 Million USD | -49.33% |
| 2009 Q4 | -4.04 Million USD | 18.36% |
| 2008 Q1 | -9.62 Million USD | -9.65% |
| 2008 Q3 | -7.06 Million USD | 47.93% |
| 2008 Q4 | -6.92 Million USD | 1.95% |
| 2008 Q2 | -13.56 Million USD | -40.97% |
| 2008 FY | -37.35 Million USD | 7.34% |
| 2007 Q3 | -10.84 Million USD | -10.96% |
| 2007 Q2 | -9.77 Million USD | -4.3% |
| 2007 Q1 | -9.36 Million USD | -3.75% |
| 2007 Q4 | -8.77 Million USD | 19.04% |
| 2007 FY | -40.31 Million USD | -29.1% |
| 2006 Q2 | -4.49 Million USD | 49.92% |
| 2006 Q4 | -9.03 Million USD | -3.39% |
| 2006 FY | -31.23 Million USD | -13.61% |
| 2006 Q1 | -8.97 Million USD | -68.92% |
| 2006 Q3 | -8.73 Million USD | -94.26% |
| 2005 Q3 | -5.64 Billion USD | 0.0% |
| 2005 FY | -27.48 Million USD | 0.0% |
| 2005 Q4 | -5.31 Million USD | 99.91% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -6605.629% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -491.497% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -66.048% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 58.862% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -217.564% |
| Better Therapeutics, Inc. | -39.76 Million USD | -28.415% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -170.635% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -177.822% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -42.576% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -41.572% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 55.418% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -2171.001% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 31.699% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 13.581% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -752.634% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -139.776% |
| Molecular Templates, Inc. | -8.12 Million USD | -528.484% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -236.414% |
| NexImmune, Inc. | -32.34 Million USD | -57.857% |
| Orgenesis Inc. | -55.36 Million USD | 7.773% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -102.106% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -65344.711% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -179.162% |
| Scopus BioPharma Inc. | -11.6 Million USD | -339.783% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 91.087% |
| Statera Biopharma, Inc. | -174.4 Million USD | 70.725% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1323.021% |
| Trevena, Inc. | -40.28 Million USD | -26.729% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -89579.278% |
| Vaccinex, Inc. | -20.25 Million USD | -152.126% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -4219.218% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -556.51% |